Literature DB >> 23381107

CEBPA-CEBPG axis as a novel promising therapeutic target in acute myeloid leukemia.

Yin-jun Lou1.   

Abstract

Entities:  

Year:  2013        PMID： 23381107      PMCID： PMC4011613          DOI： 10.1038/aps.2012.191

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN： 1671-4083            Impact factor:   6.150


× No keyword cloud information.
  10 in total

Review 1.  Transcription factors in myeloid development: balancing differentiation with transformation.

Authors:  Frank Rosenbauer; Daniel G Tenen
Journal:  Nat Rev Immunol       Date:  2007-02       Impact factor: 53.106

2.  Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML.

Authors:  Joseph M Scandura; Gail J Roboz; Michelle Moh; Ewelina Morawa; Fabienne Brenet; J Robi Bose; Luis Villegas; Usama S Gergis; Sebastian A Mayer; Cindy M Ippoliti; Tania J Curcio; Ellen K Ritchie; Eric J Feldman
Journal:  Blood       Date:  2011-05-25       Impact factor: 22.113

3.  Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.

Authors:  William Blum; Ramiro Garzon; Rebecca B Klisovic; Sebastian Schwind; Alison Walker; Susan Geyer; Shujun Liu; Violaine Havelange; Heiko Becker; Larry Schaaf; Jon Mickle; Hollie Devine; Cheryl Kefauver; Steven M Devine; Kenneth K Chan; Nyla A Heerema; Clara D Bloomfield; Michael R Grever; John C Byrd; Miguel Villalona-Calero; Carlo M Croce; Guido Marcucci
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-05       Impact factor: 11.205

4.  C/EBPγ deregulation results in differentiation arrest in acute myeloid leukemia.

Authors:  Meritxell Alberich-Jordà; Bas Wouters; Martin Balastik; Clara Shapiro-Koss; Hong Zhang; Annalisa Di Ruscio; Annalisa DiRuscio; Hanna S Radomska; Alexander K Ebralidze; Giovanni Amabile; Min Ye; Junyan Zhang; Irene Lowers; Roberto Avellino; Ari Melnick; Maria E Figueroa; Peter J M Valk; Ruud Delwel; Daniel G Tenen
Journal:  J Clin Invest       Date:  2012-11-19       Impact factor: 14.808

5.  Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellström-Lindberg; Valeria Santini; Norbert Gattermann; Ulrich Germing; Guillermo Sanz; Alan F List; Steven Gore; John F Seymour; Hervé Dombret; Jay Backstrom; Linda Zimmerman; David McKenzie; C L Beach; Lewis R Silverman
Journal:  J Clin Oncol       Date:  2009-12-21       Impact factor: 44.544

Review 6.  The role of mutations in epigenetic regulators in myeloid malignancies.

Authors:  Alan H Shih; Omar Abdel-Wahab; Jay P Patel; Ross L Levine
Journal:  Nat Rev Cancer       Date:  2012-08-17       Impact factor: 60.716

7.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Finelli; Aristoteles Giagounidis; Robert Schoch; Norbert Gattermann; Guillermo Sanz; Alan List; Steven D Gore; John F Seymour; John M Bennett; John Byrd; Jay Backstrom; Linda Zimmerman; David McKenzie; Cl Beach; Lewis R Silverman
Journal:  Lancet Oncol       Date:  2009-02-21       Impact factor: 41.316

8.  Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.

Authors:  Hagop Kantarjian; Jean-Pierre J Issa; Craig S Rosenfeld; John M Bennett; Maher Albitar; John DiPersio; Virginia Klimek; James Slack; Carlos de Castro; Farhad Ravandi; Richard Helmer; Lanlan Shen; Stephen D Nimer; Richard Leavitt; Azra Raza; Hussain Saba
Journal:  Cancer       Date:  2006-04-15       Impact factor: 6.860

9.  Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia.

Authors:  M E Huang; Y C Ye; S R Chen; J R Chai; J X Lu; L Zhoa; L J Gu; Z Y Wang
Journal:  Blood       Date:  1988-08       Impact factor: 22.113

10.  IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.

Authors:  Sevin Turcan; Daniel Rohle; Anuj Goenka; Logan A Walsh; Fang Fang; Emrullah Yilmaz; Carl Campos; Armida W M Fabius; Chao Lu; Patrick S Ward; Craig B Thompson; Andrew Kaufman; Olga Guryanova; Ross Levine; Adriana Heguy; Agnes Viale; Luc G T Morris; Jason T Huse; Ingo K Mellinghoff; Timothy A Chan
Journal:  Nature       Date:  2012-02-15       Impact factor: 69.504
  10 in total
  1 in total

Review 1.  CCAAT enhancer binding protein gamma (C/EBP-γ): An understudied transcription factor.

Authors:  Zachary Renfro; Bryan E White; Kimberly E Stephens
Journal:  Adv Biol Regul       Date:  2022-01-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.